Bayer and Onyx appear poised to expand sales of Nexavar (sorafenib). Investigators told the crowd at ASCO Sunday morning that their therapy almost doubled progression-free survival of treatment-resistant thyroid cancer patients, from a median 5.8 months in the control arm to 10.8 months in the treatment group.
Bayer and Regeneron's hard-charging eye drug has traded its way to another victory. It won a recommendation from the U.K.'s cost-effectiveness watchdogs, on the strength of a pricing discount. Previously rejected as too expensive, Eylea is now in line for routine use by Britain's National Health Service.
French health regulators say they'll usher Bayer's hormonal pill Diane 35 back onto the market, if top European watchdogs ratify the latest recommendations from a drug-safety body.
As Bloomberg reports, Germany's Der Spiegel has ferreted more details about drug research in Soviet-era East Germany, where pharma groups tied to some of the biggest names in the industry reportedly benefited from cheap clinical trials before the fall of the Berlin Wall.
Bayer has a new set of upbeat results from its long-term extension study of riociguat, a major new player in a busy field of competitors angling for a share of the market for pulmonary arterial hypertension.
France drug regulator in January yanked Bayer's contraceptive Diane-35 off the market and insisted the European Medicines Agency investigate its off-label use as an acne treatment and its risks of blood clots. The EMA has done that and has come down in support of the drug, even for the off-label use.
With the big American Society of Clinical Oncology meeting coming up in two weeks, anticipation about the coming onslaught of data is mounting. Last night, ASCO released some key abstracts for studies to be presented at the meeting, offering an aperitif to oncology-drug followers. Here is a sampling of news, some from our sister publication FierceBiotech.
Roche may be trying to unload its blood glucose meter business, reflecting continued challenges over reimbursement, and a contrast from the far better success the company has enjoyed with diagnostics development.
The approval comes just three months after the FDA granted priority review status for Alpharadin, a radiopharmaceutical from Bayer and Norway's Algeta that will now enter an increasingly competitive--and growing--market.
A group of minority Schering AG shareholders held out to the bitter end against what Bayer wanted to pay them for their shares, and they will now get the sweet deal they said they deserved.